News

Galectin Therapeutics announced positive results from its NAVIGATE trial of belapectin, a galectin-3 inhibitor, for patients with MASH cirrhosis...

Quantum BioPharma has completed the 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis (MS) drug, Lucid-21-302 (Lucid-MS)....

Medera Inc., a clinical-stage biopharmaceutical company, announced that data from its Phase 1/2a MUSIC-HFpEF clinical trial investigating its gene...

Alterity Therapeutics presented data at the 2025 International MSA Congress, highlighting positive Phase 2 results for their drug ATH434...

Cognition Therapeutics presented preclinical data at ARVO demonstrating the potential of zervimesine (CT1812) to protect retinal cells from damage...

Tiziana Life SciencesLife Sciences announced positive results from a PET scan of an Alzheimer’s patient treated with their intranasal...

Akero Therapeutics announced new analyses from its 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for pre-cirrhotic metabolic dysfunction-associated...

NurExone Biologic Inc. presented preclinical data at the ARVO annual meeting, demonstrating that its ExoPTEN therapy restored retinal activity...

Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...

UTRx Inc. submitted an Investigational New Drug (IND) application to the FDA for UTRxM1-18, a novel therapeutic targeting c-MYC...